Amber Therapeutics has announced the acquisition of UK-based Bioinduction, along with its Picostim DyNeuMo neuromodulation therapy platform.

Amber is utilising the next-generation implantable system platform to deliver closed-loop therapy for mixed urinary incontinence (Amber-UI).

For rapidly prototyping adaptive therapy algorithms, the hardware is supported by an integrated data science toolkit.

Amber-UI is currently progressing through a first human study (AURA-2) and early findings suggest that the surgical procedure and adaptive therapy are safe and feasible.

The study is anticipated to be completed early next year.

The Picostim DyNeuMo system was initially developed as a cranial implant to administer deep brain stimulation for Parkinson's disease patients.

It has been improved to support closed-loop, adaptive therapies through collaboration with a consortium of academic partners led by researchers at the University of Oxford. The system is currently undergoing several first-in-human therapy trials.

Amber CEO Aidan Crawley said: “We are very excited to announce the acquisition of Bioinduction and its Picostim-DyNeuMo platform. Our teams worked together developing the platform from concept to first-in-human trials in under two years.

“This deal formally brings together an experienced group of professionals with decades of design, clinical and manufacturing experience who can now focus on taking our first therapy to market.”

The acquisition aligns with the company's strategy to develop advanced neuromodulation therapies for patients with functional nervous system disorders.

Amber is a vertically integrated designer, developer and manufacturer of Class III Active implantable systems.